Highlights

Market Capitalization
1.2M
Book Value
$3.27
Earnings Per Share (EPS)
-4.37
Wall Street Target Price
18.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-48.31%
Return On Equity TTM
-83.97%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-13.0M
Diluted Eps TTM
-4.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-2.2%
20.15%
39.88%
76.57%
303.42%
Novo Nordisk A/s
Novo Nordisk A/s
1.56%
3.09%
46.83%
167.63%
453.76%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-1.11%
79.95%
47.56%
39.47%
212.93%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.68%
17.99%
37.89%
159.42%
173.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.86
30.86
1.59
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
46.01
46.01
2.08
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$128.4B
303.42%
30.86
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$600.4B
453.76%
46.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.1B
212.93%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.3B
173.37%
32.84
-4.74%

Insights on CWBR

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 43.9% return, outperforming this stock by 129.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 167.6% return, outperforming this stock by 266.3%

FAQs